Physiology
Conditions
Keywords
Physiology
Brief summary
Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1. The study will include physiological studies of truncally vagotomized participants and matched controls.
Interventions
DRUGTablet Sitagliptin 100mg (evening before and morning of experiments)
On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
OTHERIntestinal Fructose administration
On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
Sponsors
Rigshospitalet, Denmark
University of Copenhagen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Truncally vagotomized individuals: Inclusion Criteria: * Normal fasting plasma glucose * Normal haemoglobin concentration * Cardiaresection with a pyloroplasty * Informed consent
Exclusion criteria
* Diabetes mellitus * Disposition for diabetes mellitus * Intestinal disease (apart from cardia resection+pyloroplasty) * Disposition of inflammatory bowel disease * Intestinal resection (apart from cardia resection+pyloroplasty) * Body mass index (BMI) \> 27,5 kg/m2 * Tobacco use * Nephropathy (se-creatinine\> 130 µM and/or albuminuria) * Liver disease (ALAT and/or ASAT \>2 × refference value) * known heart condition * medicinal use, that may not be paused for 12 hours * Obstipation * swallowing difficulties * previous problems with intestinal tube placement * Latex allergy * Fructose malabsorption * Known diseases in the pharynx * Previous facial or cranial fractures * Sinusitis * Bleeding diathesis Matched controls: Inclusion Criteria: * Normal fasting plasma glucose * Normal haemoglobin concentration * Informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Insulin secretion | up to 4 hours | Evaluated by c-peptide and insulin levels - Plasma collected up to 4 hours will be analyzed for peptide hormones |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glucagon secretion | 4 hours | Plasma collected over 4 hours will be analyzed for peptide hormones |
| Glucose levels | 4 hours | Plasma collected over 4 hours will be analyzed for glucose |
| Pancreatic Polypeptide levels | 4 hours | Plasma collected over 4 hours will be analyzed for peptide hormones |
| GIP secretion | 4 hours | Plasma collected over 4 hours will be analyzed for peptide hormones |
Countries
Denmark
Outcome results
None listed